You are here: Industry Insights > Ligand

News List

Ligand Partner Jazz Pharmaceuticals Launches RYLAZE (asparaginase erwinia chrysanthemi (recombinant)-rywn), Formerly JZP458 firstwordpharma
July 22, 2021
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has launched Rylaze™(asparaginase erwinia chrysanthemi (recombinant)-rywn), also known as JZP458.
Ligand Pharmaceuticals Appoints Jennifer Cochran to its Board of Directors firstwordpharma
July 15, 2021
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) ("Ligand" or "the Company")announces the appointment of Jennifer Cochran, Ph.D. to the Company's Board of Directors
GenScript Biotech and Ligand Pharmaceuticals Enter into Global OmniAb® Licensing Agreement prnasia
June 03, 2021
GenScript Biotech Corporation along with its subsidiary, GenScript ProBio, and Ligand Pharmaceuticals Incorporated announced that they have entered into a strategic licensing agreement for Ligand's OmniAb® Platform, a multi-species antibody discovery ...
Hovione to Support Manufacture of Remdesivir for COVID-19 contractpharma
September 24, 2020
To meet Captisol demand associated with Remdesivir, Hovione will be producing per month the quantity it usually produces in one year.
Ligand to Acquire Pfenex americanpharmaceuticalreview
August 19, 2020
Ligand Pharmaceuticals and Pfenex announced the signing of a definitive agreement for Ligand to acquire all outstanding shares of Pfenex for $12.00 per share in cash or $438 million in equity value on a fully diluted basis.
Ligand Licenses VER250840 to Cumulus Oncology americanpharmaceuticalreview
May 23, 2019
Ligand Pharmaceuticals announced the signing of a license agreement granting Cumulus Oncology exclusive worldwide rights to develop and commercialize VER250840 ...
Ligand Announces OmniAb Partnership with Genagon Therapeutics americanpharmaceuticalreview
February 14, 2019
Ligand Pharmaceuticals has entered into a worldwide OmniAb partnership with Genagon Therapeutics AB, an immuno-oncology focused biotech located in Sweden.....
Ligand Announces the Close of its Acquisition of Vernalis americanpharmaceuticalreview
October 12, 2018
Ligand announces that its acquisition of Vernalis has successfully closed and Vernalis will now operate as a subsidiary of Ligand. Vernalis is a structure-based drug discovery biotechnology company with a broad pipeline of partnered programs and ongoing c
Ligand Makes Offer to Acquire Vernalis americanpharmaceuticalreview
August 10, 2018
Ligand Pharmaceuticals and Vernalis announced that Ligand has declared its firm intention to acquire the entire issued and to be issued shares of Vernalis.
Ligand to buy UK biotech Vernaliss for $43 million pharmatimes
August 10, 2018
San Diego-based Ligand is looking to snap up UK biotech Vernalis for approximately $43 million.

Previous page 1 2 Next page